CN109265469A - 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 - Google Patents
嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 Download PDFInfo
- Publication number
- CN109265469A CN109265469A CN201811340443.XA CN201811340443A CN109265469A CN 109265469 A CN109265469 A CN 109265469A CN 201811340443 A CN201811340443 A CN 201811340443A CN 109265469 A CN109265469 A CN 109265469A
- Authority
- CN
- China
- Prior art keywords
- compound
- pharmaceutically acceptable
- lymphocytic leukemia
- acid
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 thiazole heterocyclic compounds Chemical class 0.000 title claims abstract description 14
- 239000000203 mixture Substances 0.000 title abstract description 9
- 208000028018 Lymphocytic leukaemia Diseases 0.000 title abstract description 7
- 208000003747 lymphoid leukemia Diseases 0.000 title abstract description 7
- 150000001875 compounds Chemical class 0.000 claims abstract description 34
- 150000003839 salts Chemical class 0.000 claims abstract description 20
- 101000934996 Homo sapiens Tyrosine-protein kinase JAK3 Proteins 0.000 claims abstract description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 11
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 10
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims abstract description 8
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims abstract description 8
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 claims abstract description 8
- 201000003444 follicular lymphoma Diseases 0.000 claims abstract description 6
- 239000003814 drug Substances 0.000 claims description 18
- 238000002360 preparation method Methods 0.000 claims description 11
- 102100025387 Tyrosine-protein kinase JAK3 Human genes 0.000 claims description 10
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 3
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 3
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims description 3
- 239000001257 hydrogen Substances 0.000 claims description 2
- 229910052739 hydrogen Inorganic materials 0.000 claims description 2
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 208000011691 Burkitt lymphomas Diseases 0.000 abstract description 4
- 210000003719 b-lymphocyte Anatomy 0.000 abstract 1
- 208000019420 lymphoid neoplasm Diseases 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 32
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 29
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 29
- 108091000080 Phosphotransferase Proteins 0.000 description 19
- 102000020233 phosphotransferase Human genes 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 125000004527 pyrimidin-4-yl group Chemical group N1=CN=C(C=C1)* 0.000 description 16
- 229940079593 drug Drugs 0.000 description 13
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 239000000243 solution Substances 0.000 description 11
- 239000003153 chemical reaction reagent Substances 0.000 description 10
- 238000001514 detection method Methods 0.000 description 10
- DQXKOHDUMJLXKH-PHEQNACWSA-N (e)-n-[2-[2-[[(e)-oct-2-enoyl]amino]ethyldisulfanyl]ethyl]oct-2-enamide Chemical compound CCCCC\C=C\C(=O)NCCSSCCNC(=O)\C=C\CCCCC DQXKOHDUMJLXKH-PHEQNACWSA-N 0.000 description 8
- 238000004364 calculation method Methods 0.000 description 8
- 230000035755 proliferation Effects 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 206010025323 Lymphomas Diseases 0.000 description 7
- ABSXPNGWJFAPRT-UHFFFAOYSA-N benzenesulfonic acid;n-[3-[[5-fluoro-2-[4-(2-methoxyethoxy)anilino]pyrimidin-4-yl]amino]phenyl]prop-2-enamide Chemical compound OS(=O)(=O)C1=CC=CC=C1.C1=CC(OCCOC)=CC=C1NC1=NC=C(F)C(NC=2C=C(NC(=O)C=C)C=CC=2)=N1 ABSXPNGWJFAPRT-UHFFFAOYSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 229950002089 spebrutinib Drugs 0.000 description 7
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- 238000002835 absorbance Methods 0.000 description 6
- 229930192474 thiophene Natural products 0.000 description 6
- 230000002401 inhibitory effect Effects 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 210000004698 lymphocyte Anatomy 0.000 description 4
- 239000011535 reaction buffer Substances 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 description 3
- 229960001507 ibrutinib Drugs 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 2
- CYCGRDQQIOGCKX-UHFFFAOYSA-N Dehydro-luciferin Natural products OC(=O)C1=CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 CYCGRDQQIOGCKX-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- BJGNCJDXODQBOB-UHFFFAOYSA-N Fivefly Luciferin Natural products OC(=O)C1CSC(C=2SC3=CC(O)=CC=C3N=2)=N1 BJGNCJDXODQBOB-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 229940123241 Janus kinase 3 inhibitor Drugs 0.000 description 2
- 108060001084 Luciferase Proteins 0.000 description 2
- 239000005089 Luciferase Substances 0.000 description 2
- DDWFXDSYGUXRAY-UHFFFAOYSA-N Luciferin Natural products CCc1c(C)c(CC2NC(=O)C(=C2C=C)C)[nH]c1Cc3[nH]c4C(=C5/NC(CC(=O)O)C(C)C5CC(=O)O)CC(=O)c4c3C DDWFXDSYGUXRAY-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102000001253 Protein Kinase Human genes 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 description 2
- DPKHZNPWBDQZCN-UHFFFAOYSA-N acridine orange free base Chemical compound C1=CC(N(C)C)=CC2=NC3=CC(N(C)C)=CC=C3C=C21 DPKHZNPWBDQZCN-UHFFFAOYSA-N 0.000 description 2
- 230000000781 anti-lymphocytic effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- DZBUGLKDJFMEHC-UHFFFAOYSA-N benzoquinolinylidene Natural products C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000010609 cell counting kit-8 assay Methods 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- QPJVMBTYPHYUOC-UHFFFAOYSA-N methyl benzoate Chemical compound COC(=O)C1=CC=CC=C1 QPJVMBTYPHYUOC-UHFFFAOYSA-N 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 2
- 108060006633 protein kinase Proteins 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000000741 silica gel Substances 0.000 description 2
- 229910002027 silica gel Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 231100000820 toxicity test Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- HCSBTDBGTNZOAB-UHFFFAOYSA-N 2,3-dinitrobenzoic acid Chemical compound OC(=O)C1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O HCSBTDBGTNZOAB-UHFFFAOYSA-N 0.000 description 1
- AQECFYPZMBRCIA-UHFFFAOYSA-N 2,4-dichlorothieno[3,2-d]pyrimidine Chemical compound ClC1=NC(Cl)=C2SC=CC2=N1 AQECFYPZMBRCIA-UHFFFAOYSA-N 0.000 description 1
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-M 4-hydroxybutyrate Chemical compound OCCCC([O-])=O SJZRECIVHVDYJC-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-YMDCURPLSA-N D-galactopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-YMDCURPLSA-N 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 101150069380 JAK3 gene Proteins 0.000 description 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 229920000877 Melamine resin Polymers 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010070863 Toxicity to various agents Diseases 0.000 description 1
- ZZXDRXVIRVJQBT-UHFFFAOYSA-M Xylenesulfonate Chemical compound CC1=CC=CC(S([O-])(=O)=O)=C1C ZZXDRXVIRVJQBT-UHFFFAOYSA-M 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- IPBVNPXQWQGGJP-UHFFFAOYSA-N acetic acid phenyl ester Natural products CC(=O)OC1=CC=CC=C1 IPBVNPXQWQGGJP-UHFFFAOYSA-N 0.000 description 1
- 229940061720 alpha hydroxy acid Drugs 0.000 description 1
- 150000001280 alpha hydroxy acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 230000010100 anticoagulation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012131 assay buffer Substances 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 150000001649 bromium compounds Chemical class 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- KVSASDOGYIBWTA-UHFFFAOYSA-N chloro benzoate Chemical compound ClOC(=O)C1=CC=CC=C1 KVSASDOGYIBWTA-UHFFFAOYSA-N 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000000432 density-gradient centrifugation Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 229960004275 glycolic acid Drugs 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000003547 immunosorbent Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000004694 iodide salts Chemical class 0.000 description 1
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000000021 kinase assay Methods 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 150000002690 malonic acid derivatives Chemical class 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- JDSHMPZPIAZGSV-UHFFFAOYSA-N melamine Chemical compound NC1=NC(N)=NC(N)=N1 JDSHMPZPIAZGSV-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- IZYBEMGNIUSSAX-UHFFFAOYSA-N methyl benzenecarboperoxoate Chemical compound COOC(=O)C1=CC=CC=C1 IZYBEMGNIUSSAX-UHFFFAOYSA-N 0.000 description 1
- 229940095102 methyl benzoate Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 150000003891 oxalate salts Chemical class 0.000 description 1
- 229940116315 oxalic acid Drugs 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049953 phenylacetate Drugs 0.000 description 1
- WLJVXDMOQOGPHL-UHFFFAOYSA-N phenylacetic acid Chemical compound OC(=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-UHFFFAOYSA-N 0.000 description 1
- 125000004344 phenylpropyl group Chemical group 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 238000007747 plating Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- KCXFHTAICRTXLI-UHFFFAOYSA-N propane-1-sulfonic acid Chemical compound CCCS(O)(=O)=O KCXFHTAICRTXLI-UHFFFAOYSA-N 0.000 description 1
- UORVCLMRJXCDCP-UHFFFAOYSA-N propynoic acid Chemical class OC(=O)C#C UORVCLMRJXCDCP-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000013517 stratification Methods 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-L sulfite Chemical class [O-]S([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-L 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229940071104 xylenesulfonate Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途，所述嘧啶并噻唑类杂环化合物具体为通式(I)所示的化合物，通式(I)的各取代基如说明书中的定义。本发明还涉及所述通式(I)所示的化合物或其药学上可接受的盐，或含其的药物组合物通过抑制JAK3酪氨酸激酶，进而治疗肿瘤疾病，特别是用于治疗伯基特氏淋巴瘤、弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤或慢性淋巴细胞白血病的用途。
Description
技术领域
本发明涉及嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途，属于医药技术领域。
背景技术
蛋白酪氨酸激酶(protein tyrosine kinase,PTKs)通过控制细胞的信号传导通路调节细胞的生长、分化、凋亡等一系列生理生化过程，是抗肿瘤药物研发的重要靶点之一。受体型酪氨酸激酶是一类横跨细胞膜的激酶，具有配体结合的胞外结构域、跨膜结构域和起激酶作用—在磷酸化特定酪氨酸残基并且由此影响细胞增殖的胞内结构域。在众多的癌症中(如肺癌、乳腺癌、胃癌、卵巢癌、淋巴瘤)均已发现所述激酶的异常表达。
新近研究显示：淋巴细胞白血病中基本都存在JAK3基因突变，JAK-STAT抑制剂是治疗淋巴瘤患者的有效途径。正在进行三期临床研究评估的一种治疗类风湿疾病的JAK抑制剂，也能诱导细胞凋亡，促使淋巴瘤细胞株死亡(Cancer Discov.2012,2,591-597)，这为JAK3抑制剂用于治疗淋巴细胞白血病提供了一个重要依据和新的思路。
鉴于治疗白血病的迫切需要，本领域有必要开发作用机制独特，结构新颖的抗淋巴细胞白血病药物。
发明内容
本发明的目的之一在于提供一种嘧啶并噻唑类杂环化合物或其药学上可接受的盐，该类化合物具有良好的抗淋巴细胞白血病活性。
本发明的另一目的在于提供含所述嘧啶并噻唑类杂环化合物或其药学上可接受的盐的药物组合物。
本发明的再一目的在于提供所述嘧啶并噻唑类杂环化合物或其药学上可接受的盐，或所述组合物的用途。
一方面，本发明提供一种通式(I)所示的化合物或其药学上可接受的盐，所述通式(I)所示的化合物具有如下结构：
其中，
X选自NH或O；
R1选自氢、氯、甲基、氟或甲氧基；
R选自
在一些实施方式中，所述通式(I)所示的化合物具有I-1～I-9所示的结构：
优选地，所述通式(I)所示的化合物为I-3。
如上所示结构化合物为嘧啶并噻唑类杂环化合物，抗肿瘤活性性筛选显示本发明中的化合物具有较强的抑制淋巴细胞瘤细胞(Ramos细胞和Raji细胞)增殖能力，部分化合物显示出比参照药物Spebrutinib和HM71224预料不到的更加优良的抗JAK3激酶活性。作为一类结构新颖的分子，本发明中的化合物具有开发成新型高效JAK3抑制剂的潜力，对治疗相关的肿瘤疾病尤其是淋巴瘤、滤泡性淋巴瘤或慢性淋巴细胞白血病有较大的应用价值。
前述I-1～I-9所示的结构分别具有如下名称：
(I-1)N-[3-[[2-[[3-4-(2-(4-吗啉基)丙氧基)苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氧基]苯基]-2-丙烯酰胺；
(I-2)N-[3-[[2-[[3-甲基-4-(2-(4-吗啉基)丙氧基)苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺；
(I-3)N-[3-[[2-[[3-甲基-4-(2-(4-吗啉基)丙氧基)苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺；
(I-4)N-[3-[[2-[[3-氯-4-(2-(4-吗啉基)丙氧基)苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺；
(I-5)N-[3-[[2-[[4-(2-[[4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氧基]苯基]-2-丙烯酰胺；
(I-6)N-[3-[[2-[[4-(2-[[4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺；
(I-7)N-[3-[[2-[[4-(2-[[3-甲基-4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺；
(I-8)N-[3-[[2-[[4-(2-[[3-氯-4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺；
(I-9)N-[3-[[2-[[4-(2-[[2-甲基-4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺；
另一方面，本发明提供一种药物组合物，其含有有效剂量的本发明所述通式(I)所示的化合物或其药学上可接受的盐，及药用载体。
本发明所述化合物由于它们在药物中的可能用途，式(I)化合物的盐优选药物可接受的盐。本发明的化合物为碱，其中所需盐形式可以通过本领域已知的合适方法制备，包括用无机酸处理游离碱，所述无机酸例如盐酸、氢溴酸、硫酸、硝酸、磷酸等；或用有机酸处理游离碱、所述有机酸例如乙酸、三氟乙酸、马来酸、琥珀酸、扁桃酸、富马酸、丙二酸、丙酮酸、草酸、羟基乙酸、水杨酸、吡喃糖苷酸(pyranosidy1acid)，例如葡糖醛酸或半乳糖醛酸，α-羟基酸，例如柠檬酸或酒石酸，氨基酸，例如天冬氨酸或谷氨酸，芳香酸，例如苯甲酸或肉桂酸，磺酸，例如p-甲苯磺酸、甲磺酸、乙磺酸等。药学上可接受的盐的实施例包括硫酸盐、焦硫酸盐、硫酸氢盐、亚硫酸盐、亚硫酸氢盐、磷酸盐、氯化物、溴化物、碘化物、乙酸盐、丙酸盐、癸酸盐、辛酸盐、丙烯酸盐、甲酸盐、异丁酸盐、己酸盐、庚酸盐、丙酸盐(propiolates)、草酸盐、丙二酸盐、苯甲酸盐、氯苯甲酸盐、甲基苯甲酸盐、二硝基苯甲酸盐、羟基苯甲酸盐、甲氧基苯甲酸盐、邻苯二甲酸盐、苯基乙酸盐、苯基丙酸盐、苯基丁酸盐(phenylbutrates)、柠檬酸盐、乳酸盐、γ-羟基丁酸盐、羟基乙酸盐、酒石酸盐、苦杏仁酸盐和磺酸盐、例如二甲苯磺酸盐、甲磺酸盐、丙磺酸盐、萘-1-磺酸盐和萘-2-磺酸盐。
本发明的药物组合物通常含有一种本发明化合物。然而，在一些实施方案中，本发明的药物组合物含有超过一种本发明的化合物。另外，本发明的药物组合物还可任选包括一种或多种其它药学活性化合物。
本发明还提供所述嘧啶并噻唑类杂环化合物或其药学上可接受的载体，所述药物组合物通过抑制JAK3酪氨酸激酶，进而抑制肿瘤增殖的用途。具体地，该用途主要为制备用于治疗伯基特氏淋巴瘤、弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤或慢性淋巴细胞白血病的药物中的用途。
本发明提供所示的化合物或其药学上可接受的盐，或本发明所述的药物组合物在制备JAK3酪氨酸激酶抑制剂中的应用。
本发明提供所述通式(I)所示的化合物或其药学上可接受的盐，或本发明所述的药物组合物在制备治疗肿瘤的药物中的用途。优选地，所述肿瘤选自弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤和慢性淋巴细胞白血病中的一种或多种，进一步优选慢性淋巴细胞白血病。更优选地，所述用途主要通过抑制JAK3酪氨酸激酶实现的。
附图说明
图1为化合物I-3抗Ramos淋巴细胞增殖活性实验结果图。
图2为化合物I-3抗Ramos淋巴细胞增殖的形态学观察结果图。
图3为化合物I-3对PBMC细胞毒性实验结果图。
具体实施方式
以下结合具体实施例进一步描述解释本发明，但这些实施例并非意味着限制本发明的范围。
本发明实施例中未注明具体条件的实验方法，通常按照常规条件，或按照原料或商品制造厂商所建议的条件。未注明具体来源的试剂，为市场购买的常规试剂。
实施例1目标分子的制备
薄层层析硅胶板使用烟台黄海HSGF254或青岛GF254硅胶板，薄层色谱法(TLC)使用的硅胺板采用的规格是0.15mm-0.2mm，薄层层析分离纯化产品采用的规格是0.4mm-0.5mm。
本发明使用的原料主要购自可购买自国药集团化学试剂有限公司，北京偶合科技有限公司、阿拉丁化学试剂有限公司、达瑞化学品等公司。
实施例中无特殊说明，溶液是指水溶液。
实施例中无特殊说明，反应的温度为室温，为20℃-30℃。
本发明采用的技术方案如下：
化合物I-(1-9)的合成路线、试剂及条件:(条件1)二异丙基乙基胺,二氧六环,60℃,2h；(条件2)三氟乙酸,异丙醇,12h,100℃。
M-2的合成
取2,4-二氯噻吩并[3,2-D]嘧啶(7.24mmol)和中间体M-1(7.24mmol)、DIPEA(10.86mmol)于烧瓶中，加入1,4-二氧六环，60℃反应2小时，反应液减压蒸干，加水析出固体，抽滤，烘干，得固体M-2。
目标物I的合成
取氨基化合物M-3或M-4(1.0mmol)与嘧啶中间体M-2(1.0mmol)分别反应，溶于10mL 2-BuOH中，慢慢滴加三氟乙酸(1.5mmol)，升温100℃反应12小时，反应完毕后抽干溶剂，加MeOH 10mL，再加饱和碳酸氢钠析出固体，薄层层析分离纯化得目标化合物I-(1-9)。
根据以上方法合成了目标分子，所合成目标分子的理化数据如下：
(I-1)N-[3-[[2-[[3-4-(2-(4-吗啉基)丙氧基)苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氧基]苯基]-2-丙烯酰胺,1H NMR(400MHz,DMSO-d6)δ10.44(s,1H),9.36(s,1H),8.29(d,J＝5.4Hz,1H),7.73(t,J＝2.0Hz,1H),7.62(d,J＝8.3Hz,1H),7.55(d,J＝7.6Hz,2H),7.46(s,1H),7.38–7.29(m,1H),7.08(dd,J＝7.9,1.9Hz,1H),6.76(dd,J＝30.0,8.7Hz,2H),6.46(dd,J＝16.9,10.1Hz,1H),6.29(d,J＝1.8Hz,1H),5.79(dt,J＝10.2,5.0Hz,1H),4.24(s,2H),3.80(s,4H),3.15(d,J＝50.8Hz,6H)；13C NMR(101MHz,DMSO-d6)δ166.11(s),165.01(s),164.77(s),159.19(s),153.59(s),141.73(s),138.24(s),135.90(s),133.01(s),131.29(s),128.71(s),126.53(s),124.54(s),121.55(s),118.43(s),118.04(s),115.86(s),114.30(s),64.92(s),56.70(s),53.26(s)；HRMS(ESI)for C28H29N5O4S,[M+H]+理论计算:532.2013,实测:532.21043；
(I-2)N-[3-[[2-[[3-甲基-4-(2-(4-吗啉基)丙氧基)苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺,1H NMR(400MHz,DMSO-d6)δ10.41(s,1H),9.32(s,1H),8.18(d,J＝5.2Hz,1H),7.68(t,J＝2.0Hz,1H),7.58(d,J＝8.3Hz,1H),7.48(d,J＝7.6Hz,2H),7.41(s,1H),7.38–7.20(m,2H),7.00(dd,J＝8.0,2.0Hz,1H),6.70(dd,J＝30.0,8.8Hz,2H),6.40(dd,J＝16.0,10.0Hz,1H),6.20(d,J＝1.8Hz,1H),5.70(dt,J＝10.0,5.0Hz,1H),4.20(s,2H),3.80(s,4H),3.10(d,J＝50.8Hz,6H)；13C NMR(101MHz,DMSO-d6)δ166.11(s),165.00(s),164.70(s),159.10(s),153.50(s),141.68(s),138.20(s),135.90(s),133.00(s),131.20(s),128.70(s),126.50(s),124.48(s),120.11(s),118.33(s),118.00(s),115.02(s),114.20(s),64.90(s),56.52(s),53.20(s)；HRMS(ESI)forC28H30N6O3S,[M+H]+理论计算:531.2173,实测:531.2199；
(I-3)N-[3-[[2-[[3-甲基-4-(2-(4-吗啉基)丙氧基)苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺,1H NMR(400MHz,DMSO-d6)δ10.32(s,1H),8.49(s,1H),8.19(d,J＝5.4Hz,1H),7.70(t,J＝2.0Hz,1H),7.53(d,J＝0.9Hz,1H),7.40(t,J＝8.1Hz,1H),7.19(dd,J＝11.7,7.0Hz,2H),7.05(dd,J＝8.1,1.7Hz,1H),6.72(d,J＝2.7Hz,1H),6.59(dd,J＝8.7,2.6Hz,1H),6.45(dd,J＝17.0,10.1Hz,1H),6.28(dd,J＝16.9,1.9Hz,1H),5.78(dd,J＝10.1,2.0Hz,1H),3.94(t,J＝6.3Hz,2H),3.64–3.50(m,4H),2.40(dd,J＝15.6,8.0Hz,6H),2.12(s,3H),1.90–1.79(m,2H)；13C NMR(101MHz,DMSO-d6)δ166.47(s),164.94(s),164.69(s),161.04(s),156.92(s),153.48(s),141.59(s),137.82(s),133.02(s),132.24(s),131.18(s),128.69(s),128.33(s),124.45(s),118.28(s),117.79(s),117.17(s),114.09(s),112.88(s),108.21(s),67.55(s),67.10(s),56.24(s),54.74(s),27.28(s),19.65(s)；HRMS(ESI)for C29H31N5O4S,[M+H]+理论计算:546.2170,实测:546.2155；
(I-4)N-[3-[[2-[[3-氯-4-(2-(4-吗啉基)丙氧基)苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺,1H NMR(400MHz,DMSO-d6)δ10.41(s,1H),10.12(s,1H),9.51(s,1H),8.31(d,J＝5.2Hz,1H),7.76(d,J＝18.1Hz,2H),7.68–7.22(m,4H),7.02(dd,J＝46.5,8.3Hz,2H),6.64–6.02(m,2H),5.77(d,J＝10.1Hz,1H),4.01(d,J＝24.6Hz,4H),3.67(s,2H),3.19(d,J＝63.8Hz,4H),2.50(s,2H),2.13(s,2H)；13C NMR(101MHz,DMSO-d6)δ165.94(s),165.06(s),164.75(s),158.88(s),153.49(s),149.32(s),141.83(s),138.53(s),136.42(s),133.04(s),131.41(s),128.68(s),124.55(s),122.65(s),121.29(s),119.72(s),118.22(d,J＝6.7Hz),115.87(s),114.08(s),109.23(s),67.83(s),64.87(s),55.12(s),52.67(s),24.65(s)；HRMS(ESI)for C28H28ClN5O4S,[M+H]+理论计算:566.1623,实测:566.1620；
(I-5)N-[3-[[2-[[4-(2-[[4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氧基]苯基]-2-丙烯酰胺,1H NMR(400MHz,DMSO-d6)δ10.35(s,1H),9.30(s,1H),8.27(d,J＝5.4Hz,1H),7.72(t,J＝2.0Hz,1H),7.62–7.58(m,1H),7.47(dd,J＝16.8,8.6Hz,3H),7.34(d,J＝5.4Hz,1H),7.10–7.06(m,1H),6.72(d,J＝8.8Hz,2H),6.44(dd,J＝17.0,10.1Hz,1H),6.27(dd,J＝17.0,1.9Hz,1H),5.78(dd,J＝10.1,1.9Hz,1H),3.64–3.54(m,4H),3.46(s,4H),3.33(s,2H)；13C NMR(101MHz,DMSO-d6)δ167.57(s),166.15(s),165.00(s),164.73(s),159.24(s),154.01(s),153.59(s),141.69(s),138.15(s),135.48(s),132.99(s),131.32(s),128.73(s),124.58(s),121.58(s),118.45(s),118.02(s),115.65(s),114.30(s),108.60(s),67.53(d,J＝17.6Hz),46.21(s),42.97(s)；HRMS(ESI)for C27H25N5O5S,[M+H]+理论计算:532.1649,实测:532.1635；
(I-6)N-[3-[[2-[[4-(2-[[4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺,1H NMR(400MHz,DMSO-d6)δ10.28(s,1H),9.13(s,1H),8.20(d,J＝5.4Hz,1H),7.62(t,J＝2.0Hz,1H),7.62–7.60(m,1H),7.40(dd,J＝16.8,8.6Hz,3H),7.30(d,J＝5.4Hz,1H),7.10–7.00(m,2H),6.70(d,J＝8.8Hz,2H),6.40(dd,J＝16.0,10.0Hz,1H),6.20(dd,J＝17.0,1.9Hz,1H),5.70(dd,J＝10.1,1.9Hz,1H),3.64–3.50(m,4H),3.40(s,4H),3.30(s,2H)；13C NMR(101MHz,DMSO-d6)δ167.50(s),166.10(s),165.00(s),164.70(s),159.20(s),154.00(s),153.50(s),141.60(s),138.10(s),135.40(s),132.90(s),131.30(s),128.70(s),124.50(s),121.50(s),118.40(s),118.00(s),115.60(s),114.28(s),108.45(s),67.50(d,J＝16.0Hz),46.20(s),42.97(s)；HRMS(ESI)for C27H26N6O4S,[M+H]+理论计算:531.1809,实测:531.1756；
(I-7)N-[3-[[2-[[4-(2-[[3-甲基-4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺；1H NMR(400MHz,DMSO-d6)δ10.32(s,1H),8.51(s,1H),8.19(d,J＝5.4Hz,1H),7.70(t,J＝2.1Hz,1H),7.56–7.50(m,1H),7.41(t,J＝8.1Hz,1H),7.23(d,J＝5.4Hz,1H),7.19(d,J＝8.7Hz,1H),7.09–7.03(m,1H),6.75(d,J＝2.8Hz,1H),6.62(dd,J＝8.7,2.7Hz,1H),6.44(dd,J＝17.0,10.1Hz,1H),6.27(dd,J＝17.0,2.0Hz,1H),5.78(dd,J＝10.1,2.0Hz,1H),3.66–3.54(m,4H),3.46(d,J＝3.3Hz,4H),3.34(s,2H),2.12(s,3H)；13C NMR(101MHz,DMSO-d6)δ167.53(s),166.45(s),164.96(s),164.70(s),161.01(s),156.27(s),153.48(s),141.59(s),137.80(s),135.69(s),133.01(s),132.70(s),131.20(s),128.71(s),128.32(s),124.51(s),118.34(s),117.84(s),117.31(s),114.08(s),113.07(s),108.28(s),67.45(s),46.20(s),42.98(s),19.70(s)；HRMS(ESI)for C28H27N5O5S,[M+H]+理论计算:546.1806,实测:546.1790；
(I-8)N-[3-[[2-[[4-(2-[[3-氯-4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺,1H NMR(400MHz,DMSO-d6)δ10.34(s,1H),9.47(s,1H),8.30(d,J＝5.4Hz,1H),7.73(dd,J＝8.7,6.7Hz,2H),7.64–7.57(m,1H),7.56–7.25(m,3H),7.13–7.03(m,1H),6.85(d,J＝9.1Hz,1H),6.43(dd,J＝17.0,10.1Hz,1H),6.26(dd,J＝17.0,2.0Hz,1H),5.79–5.75(m,1H),4.83(s,2H),3.71–3.50(m,4H),3.46(s,4H)；13C NMR(101MHz,DMSO)δ16-d67.05(s),165.94(s),165.04(s),164.71(s),158.90(s),153.47(s),149.17(s),141.79(s),138.45(s),136.17(s),133.01(s),131.41(s),128.69(s),124.58(s),122.12(s),121.39(s),119.61(s),118.23(d,J＝10.7Hz),115.32(s),114.04(s),109.19(s),68.24(s),67.44(s),46.24(s),43.02(s)；HRMS(ESI)forC27H24ClN5O5S,[M+H]+理论计算:566.1259,实测:566.1265；
(I-9)N-[3-[[2-[[4-(2-[[2-甲基-4-[((1-吗啡啉)乙酰基)氧基]苯基]氨基]噻吩并[3,2-D]嘧啶-4-基]氨基]苯基]-2-丙烯酰胺,1H NMR(400MHz,DMSO-d6)δ10.18(s,1H),8.50(s,1H),8.10(d,J＝5.6Hz,1H),7.78(t,J＝2.0Hz,1H),7.52–7.50(m,2H),7.40(t,J＝8.0Hz,1H),7.20(d,J＝5.4Hz,1H),7.10(d,J＝8.6Hz,1H),7.08–7.00(m,1H),6.58(d,J＝2.8Hz,1H),6.60(dd,J＝8.7,2.7Hz,1H),6.40(dd,J＝17.0,10.0Hz,1H),6.26(dd,J＝17.0,2.0Hz,1H),5.70(dd,J＝10.6,2.0Hz,1H),3.66–3.48(m,4H),3.40(d,J＝3.3Hz,4H),3.30(s,2H),2.10(s,3H)；13C NMR(101MHz,DMSO-d6)δ167.18(s),166.42(s),164.90(s),164.60(s),161.00(s),156.20(s),153.40(s),141.50(s),137.70(s),135.60(s),133.00(s),132.25(s),131.29(s),128.66(s),128.24(s),124.50(s),118.30(s),117.80(s),117.30(s),114.00(s),113.12(s),108.20(s),67.40(s),46.10(s),42.50(s),19.59(s)；HRMS(ESI)for C28H28N6O4S,[M+H]+理论计算:545.1966,实测:545.1906。
目标分子成盐的方法
无机酸盐的制备方法：取目标分子(1mmol)溶于10mL无水甲醇中，冰浴下，慢慢滴加无机酸(1mmol)的5mL无水甲醇溶液，滴加完毕，于此温度下搅拌30分钟，然后常温蒸除甲醇，即得目标分子的无机酸盐。
有机酸盐的制备方法：取目标分子(1mmol)溶于10mL无水甲醇中，冰浴下，慢慢滴加有机酸(1mmol)的5mL干燥乙醚，滴加完毕，于此温度下搅拌30分钟，然后常温蒸除溶剂，即得目标分子的有机酸盐。
两个目标分子混合物的制备
取等摩尔量(1mmol)的上述两个目标分子于无水甲醇中(5mL)，室温搅拌10分钟，常温蒸除溶剂，即得目标分子的混合物。
实施例2目标分子生物活性评价
1、体外对受体酪氨酸激酶抑制活性测试方法
(1)制备激酶检测缓冲液
①在室温融解激酶检测缓冲液(Kinase Detection Buffer)，观察是否有沉淀。
②如果出现沉淀，就在37℃孵育(Kinase Detection Buffer)15分钟并经常摇动，溶解沉淀。或者，小心吸走上清，去除沉淀。
(2)制备激酶检测试剂
①使用前在室温平衡激酶检测缓冲液(Kinase Detection Buffe)和激酶检测底物(Kinase Detection Substrate)。
②将激酶检测缓冲液(Kinase Detection Buffer)全部倒进装有激酶检测底物(Kinase Detection Substrate)的棕色瓶中，使冻干粉底物溶解，这样就制成了激酶检测试剂。
③轻轻震荡、涡旋或颠倒混匀，成为均质溶液，底物应在1分钟内溶解。
④激酶检测试剂配好后应立即使用，或分装存于-20℃，我们认为配好的试剂经过几次冻融后循环信号活性都没有损失。
(3)制作ATP转化成ADP的标准曲线
①用1×激酶反应缓冲液(kinase reaction buffer)稀释试剂盒提供的UltraPure ATP和ADP，制成900μL 50μM ATP和500μL 50μM ADP。
②将上一步配好的50μM ATP和50μM ADP溶液按表1所示在384孔板A1-A12中混合，模拟每个转化百分比的ATP和ADP的浓度，混合好。
表1.制备50μM系列ATP+ADP标准品
③每孔加入5μL的ADP-GloTM试剂来终止激酶反应。在室温孵育40分钟。
④每孔加入10μL激酶检测试剂(Kinase Detection Reagent)将ADP转化成ATP，并引进萤光素酶和萤光素来检测ATP。
⑤在室温孵育30-60分钟，用多功能酶标仪测量萤光并记录萤光值。
⑥绘制ATP转化成ADP的标准曲线。
(4)确定激酶抑制物的IC50值
①按照promega试剂盒说明书配制1×激酶反应缓冲液(kinase reactionbuffer)，2.5×50ng/μL激酶和2.5×0.5μg/μL底物和125μM ATP。
②在无酶对照孔中加入3μL 1×激酶反应缓冲液(kinase reaction buffer)，2μL2.5×0.5μg/μL底物和125μM ATP。在阴性对照孔中加入1μL 1×激酶反应缓冲液(kinasereaction buffer)，2μL 2.5×50ng/μL激酶，2μL 2.5×0.5μg/μL底物和125μM ATP。在测试孔中加入1μL 5×待测药物，2μL2.5×50ng/μL激酶，2μL 2.5×0.5μg/μL底物和125μM ATP。
③混合好平板，孵育60分钟。
④每孔加入5μL的ADP-GloTM试剂来终止激酶反应。在室温孵育40分钟。
⑤每孔加入10μL激酶检测试剂(Kinase Detection Reagent)将ADP转化成ATP，并引进萤光素酶和萤光素来检测ATP。在室温孵育30-60分钟，用多功能酶标仪测量萤光并记录萤光值。
⑥结果分析，结果如表2所示。
2、抑制JAK3高表达细胞生长实验(CCK-8检测法)
(1)细胞类型及选择：Ramos细胞(人Burkitt's淋巴瘤细胞，JAK3激酶高表达)、Raji细胞(人Burkitt's淋巴瘤细胞，JAK3激酶高表达)、Raji细胞(人NAMAWAL淋巴瘤细胞，JAK3激酶高表达)。
(2)细胞接种：收集对数生长期细胞，调整细胞悬液浓度，以每孔4×103个细胞，每孔体积100μL接种到96孔板，每组设3个复孔(边缘孔用无菌PBS填充)；
(3)细胞培养：细胞接种后，对照组用10％FBS RPMI-1640培养，实验组分别用10μL不同浓度梯度的Spebrutinib或Ibrutinib(1.25-40μmol/L)、各不同药物(1.25-40μmol/L)干预，37℃，5％CO2培养箱中继续培养(按实验要求分别培养不同时间)；
(4)呈色：两组细胞分别于培养48h后加入10μL CCK-8溶液(5mg/ml)，4h后终止培养，于摇床上低速振荡10min，使结晶充分溶解；
(5)比色：在酶联免疫检测仪上测定各孔光度值(OD值)，选择450nm波长，以无细胞的即RPMl-1640培养液空白孔调零，测各孔的吸光度值。实验重复三次；
(6)记录结果：细胞生长抑制率＝(对照组吸光度值—实验组吸光度值)/对照组吸光度值×100％，细胞增殖率＝(实验组吸光度值/对照组吸光度值)×100；
(7)绘制细胞生长曲线：以时间为横坐标，抑制率/增殖率为纵坐标绘制细胞生长曲线。在GraphPad软件中的GraphPad Prism作图软件中针对抑制剂浓度做图，以便由log[抑制剂]相对于反应，可变斜率模型估算出IC50。
测试结果如表2所示，表2显示所获得的化合物在抑制JAK3激酶和抗肿瘤细胞增殖中的活性效果(A:1-10nM；B:10-50nM；C:1-10μM；D:10-20μM)。
表2
同时，本实验发现化合物I-3对Ramos细胞的增殖活性与时间和浓度有着很大的关系，如图1所示，随着浓度的增大，细胞存活率减小，尤其72h后的Ramos细胞在药物浓度达10μmol/L时，几乎不能存活，明显高于48h，由此可证明本药物属于浓度和时间依赖性药物。此外，与参照药Spebrutinib相比，化合物I-3在72h后对Ramos的杀伤效果有了出其不意的提高。另外，图2中显示的给药后的细胞形态和数量也进一步证明了，化合物I-3较Spebrutinib的抗Ramos细胞活性有了明显增强。
3、活性药物毒性试验
外周血单个核细胞(Peripheral blood mononuclear cell,PBMC)包含淋巴细胞、单核细胞(monocyte)、树突状细胞和其它少量细胞(造血干细胞等)。对其进行毒性试验可以证明本发明的药物是否对正常免疫细胞具有杀伤力。目前国内外分离PBMC的常用方法是葡聚糖-泛影葡胺密度梯度离心法，实验步骤如下：
(1)采血并稀释：静脉取血2ml，加入含ACD抗凝溶液的试管中，混匀，使血液抗凝。用PBS溶液将抗凝血稀释1倍；
(2)加样：吸取2ml淋巴细胞分层液(天津TBD)置于刻度离心管中，然后将离心管倾斜45°角，用毛细滴管将稀释的全血沿管壁缓慢加至分离液上面，应注意保持两者界面清晰；
(3)离心：在18℃～20℃下，用水平离心机以2000r/min离心20min。离心后从管底至液面分四层，依次为红细胞和粒细胞层、分层液层、单个核细胞层、血浆层；
(4)回收：用毛细吸管轻轻插到混浊带，沿管壁轻轻吸出此层细胞，移入另一支离心管中。即要吸取所有单个核细胞，又要避免吸取过多的分层液或血浆，以免混入其他细胞成分；
(5)洗涤：用PBS液洗涤细胞3次。第一次2000r/min，10min；第2～3次1500r/min，10min，可去掉大部分混杂的血小板；
(6)将沉淀细胞悬于培养基中备用；
(7)计数铺板：调整细胞悬液浓度，以每孔2.5×105个细胞，每孔体积500μL接种到24孔板，每组设2个复孔；
(8)细胞培养：细胞接种后，对照组用10％FBS RPMI-1640培养，实验组分别用50μL不同浓度梯度的Spebrutinib(5-20μmol/L)、I-3(5-20μmol/L)干预，37℃，5％CO2培养箱中继续培养(按实验要求分别培养不同时间)；
(9)染色：培养24h后加入20μL 1μg/μl AO(吖啶橙)，20μL 1μg/μl PI(碘化丙啶)染色5min，倒置荧光显微镜下观察并拍照。
(10)测试结果如图3所示，图3是化合物I-3对PBMC细胞毒性数据。
由表2的生物活性结果表明，本发明中的分子对JAK3激酶有较强的抑制效果(IC50＝1-10nM)，达到纳摩尔水平的活性级别，比参照药Ibrutinib和Spebrutinib的活性有了明显提高。抗细胞增殖活性结果揭示，大部分化合物对B淋巴肿瘤细胞Ramos和Raji有非常有效的抑制作用，IC50值在1-10μM之间，优于参照药Ibrutinib和Spebrutinib(10-20μM)。同时图3显示,化合物I-3的细胞毒性也比Spebrutinib显著减小，在保持药物活性的同时减轻药物的毒性，具有潜在的药用价值。综上所述，本发明的化合物对治疗JAK3酪氨酸激酶引起的疾病具有很深刻的潜在意义，特别是用于治疗弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤或慢性淋巴细胞白血病。预示此类分子具有开发成新型高效JAK3酪氨酸激酶抑制剂的潜力。
以上所述仅是本发明的优先实施方式，应当指出，对于本技术领域的普通技术人员来说，在不脱离本发明技术原理的前提下，还可以做出若干改进和润饰，这些改进和润饰也应视为本发明的保护范围。
Claims (9)
1.一种通式(I)所示的化合物或其药学上可接受的盐，所述通式(I)所示的化合物具有如下结构：
其中，
X选自NH或O；
R1选自氢、氯、甲基、氟或甲氧基；
R选自
2.根据权利要求1所述的通式(I)所示的化合物或其药学上可接受的盐，其中，所述通式(I)所示的化合物具有I-1～I-9所示的结构：
3.根据权利要求1所述的通式(I)所示的化合物或其药学上可接受的盐，其中，所述通式(I)所示的化合物为I-3。
4.一种药物组合物，其含有有效剂量的权利要求1～3中任一项所述通式(I)所示的化合物或其药学上可接受的盐，及药用载体。
5.权利要求1～3中任一项所述通式(I)所示的化合物或其药学上可接受的盐，或权利要求4所述的药物组合物在制备JAK3酪氨酸激酶抑制剂中的应用。
6.权利要求1～3中任一项所述通式(I)所示的化合物或其药学上可接受的盐，或权利要求4所述的药物组合物在制备治疗肿瘤的药物中的用途。
7.根据权利要求6所述的用途，其中，所述肿瘤选自弥漫性大B细胞淋巴瘤、滤泡性淋巴瘤和慢性淋巴细胞白血病中的一种或多种。
8.根据权利要求7所述的用途，其中，所述肿瘤为慢性淋巴细胞白血病。
9.根据权利要求5～8中任一项所述的用途，其中，所述用途主要通过抑制JAK3酪氨酸激酶实现的。
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811340443.XA CN109265469A (zh) | 2018-11-12 | 2018-11-12 | 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 |
| PCT/CN2019/112958 WO2020098466A1 (zh) | 2018-11-12 | 2019-10-24 | 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811340443.XA CN109265469A (zh) | 2018-11-12 | 2018-11-12 | 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109265469A true CN109265469A (zh) | 2019-01-25 |
Family
ID=65193014
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201811340443.XA Pending CN109265469A (zh) | 2018-11-12 | 2018-11-12 | 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN109265469A (zh) |
| WO (1) | WO2020098466A1 (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020098466A1 (zh) * | 2018-11-12 | 2020-05-22 | 大连医科大学 | 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 |
| CN112891357A (zh) * | 2019-12-03 | 2021-06-04 | 大连医科大学 | 嘧啶杂环类化合物治疗纤维化疾病的新用途 |
| CN116102572A (zh) * | 2021-11-09 | 2023-05-12 | 中国医学科学院药物研究所 | 噻吩并嘧啶类化合物及其制备方法、用途和药物组合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9908884B2 (en) * | 2009-05-05 | 2018-03-06 | Dana-Farber Cancer Institute, Inc. | EGFR inhibitors and methods of treating disorders |
| US20110207736A1 (en) * | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
| RS55783B1 (sr) * | 2010-06-23 | 2017-07-31 | Hanmi Science Co Ltd | Novi derivati fuzionisanog pirimidina za inhibiciju aktivnosti tirozin kinaze |
| CN106565614A (zh) * | 2016-11-16 | 2017-04-19 | 大连医科大学 | 二苯胺基嘧啶类化合物、组合物及用途 |
| CN109265469A (zh) * | 2018-11-12 | 2019-01-25 | 大连医科大学附属第医院 | 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 |
-
2018
- 2018-11-12 CN CN201811340443.XA patent/CN109265469A/zh active Pending
-
2019
- 2019-10-24 WO PCT/CN2019/112958 patent/WO2020098466A1/zh active Application Filing
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020098466A1 (zh) * | 2018-11-12 | 2020-05-22 | 大连医科大学 | 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 |
| CN112891357A (zh) * | 2019-12-03 | 2021-06-04 | 大连医科大学 | 嘧啶杂环类化合物治疗纤维化疾病的新用途 |
| CN116102572A (zh) * | 2021-11-09 | 2023-05-12 | 中国医学科学院药物研究所 | 噻吩并嘧啶类化合物及其制备方法、用途和药物组合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2020098466A1 (zh) | 2020-05-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107400093A (zh) | 2,4‑二苯胺基嘧啶类化合物、组合物及用途 | |
| WO2020098466A1 (zh) | 嘧啶并噻唑类杂环化合物，组合物及其治疗淋巴细胞白血病的用途 | |
| KR20100103661A (ko) | ＴＮＦ-α 합성의 조절자 및 ＰＤＥ4 억제제로서 3고리 화합물 | |
| CN108383846A (zh) | 巴瑞克替尼a晶型及其制备方法 | |
| CN111909101B (zh) | 一种egfr激酶抑制剂及其在制备抗癌药物方面的应用 | |
| JP2008505084A (ja) | フラノピリミジン | |
| CA2987466A1 (en) | Use of pteridinone derivative serving as egfr inhibitor | |
| CN111499641B (zh) | 一种jak抑制剂及其制备方法 | |
| AU2016274961A1 (en) | Adipate forms and compositions of biaryl inhibitors of Bruton's tyrosine kinase | |
| CN102140093A (zh) | 吡啶酮酰胺类衍生物、其制备方法及其在医药上的应用 | |
| CN110028509B (zh) | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 | |
| JP7351061B2 (ja) | 縮合環ピリミジン系化合物の塩、結晶形並びにその製造方法と使用 | |
| CN106831812B (zh) | 含联芳基酰胺结构的杂环并嘧啶或吡嗪类化合物及其应用 | |
| CN108164525B (zh) | 一种抗肿瘤化合物的制备方法和用途 | |
| CN108610295B (zh) | 嘧啶类化合物，组合物及其在治疗淋巴瘤白血病中的用途 | |
| CN107235931B (zh) | 新型嘧啶类抗肿瘤化合物及其制备方法与用途 | |
| CN106749042A (zh) | 磺酰胺基嘧啶类化合物，组合物及用途 | |
| CN116648247A (zh) | 吡唑取代的咪唑并[1,2-a]喹喔啉衍生物的盐型及晶型 | |
| EP3896063B1 (en) | Crystalline forms of the syk inhibitor 5-fluoro-1-methyl-3-[[5-[4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-(1h-pyrazol-3-yl)-2(1h)-quinolinone hydrochloride salt (1:1) | |
| CN105693729B (zh) | 吲哚并 [ 3 , 2 ‑ a ] 咔唑衍生物及其应用 | |
| CN106831779B (zh) | 一类jak激酶抑制剂的新化合物 | |
| CN106565782B (zh) | 磷酰基嘧啶类化合物、组合物及用途 | |
| TW201738227A (zh) | 一種稠環化合物、其製備方法和應用及其中間體化合物 | |
| CN104177342B (zh) | 杂环基取代的吲哚并萘酮衍生物及其医药用途 | |
| CN108658874B (zh) | 硫代嘧啶杂环类抗肿瘤化合物及其制备方法与用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190125 |